Scleritis Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

Scleritis is a condition in which the sclera, the tissue covering the back of the eyeball, is affected. Scleritis is a growing market. Its estimated size in 2024 is $ 750,000, and by 2035 it is projected to reach $ 1,200,000. This growth represents a compound annual growth rate (CAGR) of 4.4% between 2025 and 2035. The increasing prevalence of autoimmune diseases, which often cause scleritis, and the growing geriatric population are the main factors driving this upward trend. In addition, advances in diagnostics and therapies are improving patient outcomes and driving growth. The major players in the scleritis market are Novartis, AbbVie, and Regeneron. These companies are pursuing strategies such as collaborations, investment in R&D, and the launch of new products for scleritis and other conditions. The introduction of biological and targeted therapies has revolutionized treatment and is also driving growth. These developments will continue to shape the scleritis market, presenting opportunities for stakeholders and investors.

Regional Market Size

Regional Deep Dive

The Scleritis Market is characterized by an increasing awareness of eye diseases and the availability of advanced treatment options in various regions. In North America, the market is driven by a high prevalence of autoimmune disorders, which are closely related to scleritis, and a well-developed health care system that supports the development of new therapies. In Europe, the regulatory framework is diverse, which influences the approval of drugs. In Asia-Pacific, the market is driven by increasing investments in health care and rising patient awareness. In the Middle East and Africa, the market is characterized by limited access to medical resources, but is gradually improving due to government initiatives. In Latin America, the market is characterized by an increasing demand for ophthalmological treatments, due to the high prevalence of scleritis and related conditions, and the growing middle class and health care reforms.

Europe

• The European Medicines Agency (EMA) has streamlined the approval process for innovative therapies, which is likely to accelerate the availability of new treatments for scleritis in the region.
• Recent collaborations between pharmaceutical companies and research institutions, such as Novartis and the University of Oxford, are focusing on developing targeted therapies for scleritis, enhancing treatment efficacy.

Asia Pacific

• Countries like India and China are investing heavily in healthcare infrastructure, which is expected to improve access to scleritis treatments and increase patient awareness.
• The rise of telemedicine in the region is facilitating remote consultations and follow-ups for scleritis patients, making it easier for them to receive timely care.

Latin America

• Healthcare reforms in Brazil and Mexico are enhancing access to ocular treatments, which is likely to boost the scleritis market as more patients seek care.
• Local pharmaceutical companies are beginning to invest in research and development for scleritis treatments, indicating a growing recognition of the condition's impact on public health.

North America

• The FDA has recently approved new biologic therapies for autoimmune conditions, which are expected to significantly impact the treatment landscape for scleritis, providing patients with more effective options.
• Organizations like the American Academy of Ophthalmology are increasing awareness and education about scleritis, leading to earlier diagnosis and treatment, which is crucial for patient outcomes.

Middle East And Africa

• Government initiatives in countries like South Africa are focusing on improving healthcare access, which is crucial for the diagnosis and treatment of scleritis.
• Non-profit organizations are working to raise awareness about autoimmune diseases, including scleritis, which is expected to lead to increased patient engagement and treatment adherence.

Did You Know?

“Scleritis is often associated with systemic autoimmune diseases, with up to 50% of patients having an underlying condition such as rheumatoid arthritis or lupus.” — American Journal of Ophthalmology

Segmental Market Size

Scleritis is a market which is currently experiencing steady growth, due to increased awareness of eye diseases and advances in treatment. The prevalence of autoimmune diseases, which are often associated with scleritis, is on the rise, as is the development of targeted therapies which can improve patient outcomes. Support from the regulatory authorities for the development of new therapies is also creating a more favourable environment for market expansion. The current market for scleritis therapies is in its mature phase, with several major companies developing effective therapies. The main therapies used are corticosteroids and immunesuppressants, which are used in clinical settings, especially ophthalmology practices. However, a number of factors are combining to stimulate the market. These include the increased emphasis on personalised medicine, and the use of telemedicine for patient care. The development of new therapies, such as biosimilars and advanced diagnostics, is also influencing the market, as these enable more accurate diagnosis and treatment.

Future Outlook

The scleritis market is expected to grow at a CAGR of 4.38% from 2024 to 2035. This growth is based on the growing prevalence of autoimmune diseases and the growing awareness of scleritis as a serious eye disease. As the global health care system is improved, the diagnosis and treatment of scleritis will improve, which will lead to better patient compliance and treatment adherence. The penetration of targeted therapies and biologicals in the scleritis treatment market is expected to reach about 30% by 2035, driven by the development of new therapies and the development of precision medicine. The integration of artificial intelligence into diagnostic methods and the development of minimally invasive surgical methods are expected to change the scleritis treatment paradigm. In addition, government policies to improve access to health care and reduce the burden of chronic diseases will also play a key role in the development of the market. Telemedicine and digital health solutions are expected to improve the management of patients and follow-up care, and thus enhance the treatment effect. The evolution of the market requires that all parties pay attention to these changes and that they adapt their strategies to the increasing demand for scleritis treatment.